At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARVN Arvinas Holding Company LLC
Closed 10-23 16:00:00 EDT
7.30
-0.42
-5.44%
盘后7.50
+0.20+2.74%
19:30 EDT
High7.70Low7.20Vol651.57K
Open7.70D1 Closing7.72Amplitude6.48%
Mkt Cap477.32MTradable Cap413.69MTotal Shares65.39M
T/O4.76MT/O Rate1.15%Tradable Shares56.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Big Pharma is Pouring Billions into a New Class of 'Protein Degrader' Drugs
Dow Jones  ·  10-15
Big Pharma is Pouring Billions into a New Class of 'Protein Degrader' Drugs
Arvinas: Findings Support Evaluation of Arv-102 as a Therapeutic Approach for Neurodegenerative Diseases Associated with Lrrk2 Dysregulation
THOMSON REUTERS  ·  10-07
Arvinas: Findings Support Evaluation of Arv-102 as a Therapeutic Approach for Neurodegenerative Diseases Associated with Lrrk2 Dysregulation
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of Arv-102 in Patients with Parkinson’s Disease
THOMSON REUTERS  ·  10-07
Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of Arv-102 in Patients with Parkinson’s Disease
Arvinas : Phase 1 Arv-102 Showed Dose-Dependent Improvements in Eye Movement in Parkinson's Patients
THOMSON REUTERS  ·  10-07
Arvinas : Phase 1 Arv-102 Showed Dose-Dependent Improvements in Eye Movement in Parkinson's Patients
Arvinas Reports Phase 1 Parkinson’s Trial Data Showing ARV-102-Linked Gains in Oculomotor Measure
Reuters  ·  10-07
Arvinas Reports Phase 1 Parkinson’s Trial Data Showing ARV-102-Linked Gains in Oculomotor Measure
Arvinas to Present Phase 1 Biomarker Data for ARV-102 Parkinson’s Trial at 2026 MDS Congress
Reuters  ·  10-02
Arvinas to Present Phase 1 Biomarker Data for ARV-102 Parkinson’s Trial at 2026 MDS Congress
Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer
Reuters  ·  10-01
Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer
Arvinas Grants New Hire Stock Option for 64,766 Shares, 42,388 RSUs Under NASDAQ Inducement Rule
Reuters  ·  09-30
Arvinas Grants New Hire Stock Option for 64,766 Shares, 42,388 RSUs Under NASDAQ Inducement Rule
Arvinas Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-30
Arvinas Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Arvinas Doses First Patient in Phase 1/2 Trial of HPK1 Degrader ARV-6723 in Advanced Solid Tumors
Reuters  ·  09-28
Arvinas Doses First Patient in Phase 1/2 Trial of HPK1 Degrader ARV-6723 in Advanced Solid Tumors
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of Arv-6723, the Company’s First Immuno-Oncology Candidate
THOMSON REUTERS  ·  09-28
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of Arv-6723, the Company’s First Immuno-Oncology Candidate
Arvinas Grants 45,696 RSUs to Newly Hired Employee Under NASDAQ Inducement Award Plan
Reuters  ·  09-02
Arvinas Grants 45,696 RSUs to Newly Hired Employee Under NASDAQ Inducement Award Plan
Arvinas Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-02
Arvinas Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
MT Newswires Live  ·  08-11
Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says
Arvinas Price Target Cut to $21.00/Share from $24.00 by Citigroup
Dow Jones  ·  08-10
Arvinas Price Target Cut to $21.00/Share from $24.00 by Citigroup
Citi Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)
TIPRANKS  ·  08-10
Citi Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)
Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating
MT Newswires Live  ·  08-10
Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating
Arvinas Posts Corporate Presentation Highlighting Protac Degrader Pipeline in Oncology and Neurology
Reuters  ·  08-07
Arvinas Posts Corporate Presentation Highlighting Protac Degrader Pipeline in Oncology and Neurology
Arvinas Launches New Cancer Combo Trial, Adding Fresh Optionality to ARVN
TIPRANKS  ·  08-07
Arvinas Launches New Cancer Combo Trial, Adding Fresh Optionality to ARVN
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)
TIPRANKS  ·  08-05
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN)

Introduction

Company Name.
Arvinas Holding Company LLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Issue price:
--